相关实验视频

Updated: Feb 26, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

在复发多发性骨髓瘤中恢复骨修饰剂并不能改善结果:现实世界的分析

Malcolm Su¹, Adeel M Khan^1,2, Andrew J Cowan³

¹Department of Internal Medicine, University of Texas Southwestern, Dallas, Texas, USA.

British journal of haematology

|February 24, 2026

概括

骨修饰剂 (BMA) 在复发性多发性髓瘤中没有明显的益处. 这项研究发现,在复发后恢复BMA时,无进展或整体存活率没有显著差异.

科学领域:

血液学血液学血液学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

骨修饰剂 (BMA) 是最初多发性骨髓瘤治疗的标准.
它们在现代复发性/耐火性多发性骨髓瘤 (RRMM) 中的作用尚不清楚.
在疾病复发后BMA疗效的数据有限.

研究的目的:

评估恢复骨修饰剂 (BMA) 对复发/耐药多发性骨髓瘤 (RRMM) 患者的影响.
分析基于BMA使用后复发的无进展生存率 (PFS) 和总生存率 (OS).
在RRMM中为BMA重新启动提供临床决策信息.

主要方法:

在2014-2023年期间诊断出RRMM的1112名美国患者的回顾性分析.
在复发时接受BMA的患者与推迟使用BMA的患者之间的结局的比较.
使用考克斯比例危险模型进行统计分析,以调整相关共变量.

主要成果:

56.9%的RRMM患者在复发后接受了BMA.
在BMA-deferred (10.1个月) 和BMA-received (9.2个月) 组之间,PFS中位数没有显著差异 (p=0.08).
在BMA-deferred (39.6个月) 和BMA-received (51.5个月) 组 (p=0.10) 之间,在中位数OS上没有显著差异.

结论:

在复发性/耐药性多发性骨髓瘤环境中恢复骨修饰剂似乎不会在现代改善PFS或OS.
这些发现表明,需要针对RRMM中BMA使用的个性化方法.
需要进一步的研究来优化BMA决策在复发性多发性髓瘤.

关键词:

骨修饰剂是一种骨修饰剂.这里没有denosumab.多发性骨髓瘤是多发性骨髓瘤的一种.支持性护理支持性护理索莱德龙酸是什么意思?索莱德龙酸是什么意思?

更多相关视频

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation

Published on: April 14, 2016

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...